Dysregulation of acetylcholine receptors, in particular the M1 muscarinic receptor, has received considerable interest in AD research, as this GPCR is implicated in memory consolidation59, 60, 61 and as acetylcholinesterase (AChE) inhibitors remain among first-line AD therapeutics. This evidence concerns the gene ACHE and Alzheimer disease.